Mission Pharmacal Company, Inc. – Trademark Portfolio

Entity Type: 03

Mission Pharmacal Company, Inc. holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. The owner is based in San Antonio, TX.

P.O. Box 1676

San Antonio, TX 78296

26 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (26 results)

Trademark Classifications

Mission Pharmacal Company, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (22 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (4 filings)

Surgical, medical, dental and veterinary apparatus and instruments

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does Mission Pharmacal Company, Inc. have?

Mission Pharmacal Company, Inc. has 26 U.S. trademarks filed with the USPTO.

What trademark classes does Mission Pharmacal Company, Inc. file in?

Mission Pharmacal Company, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 35 (Advertising & Business), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is Mission Pharmacal Company, Inc.'s trademark registration success rate?

Mission Pharmacal Company, Inc. has a 0% trademark registration rate, with 0 out of 26 resolved applications resulting in successful registration. Currently, 0 applications are pending review.